Xeris Biopharma Holdings, Inc.
XERS is undervalued
NASDAQ · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$8.74
MARKET PRICE
$9.97
FAIR PRICE
$1.23
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy XERS?
No one has priced XERS yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when XERS's fair price changes
Push notifications when XERS's valuation shifts. Available on iOS and Android.
FPI RATING
Consistent growth trajectory, but expensive valuation relative to fundamentals and elevated debt levels.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$7.98
Fair price × 0.80
DISTANCE
8.7%
Price to entry level
At the current price of $8.74, XERS trades 8.7% above the conservative entry level of $7.98. This entry level represents a 20% margin of safety below the calculated fair price of $9.97 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate XERS's fair price
Xeris Biopharma Holdings, Inc.'s fair price of $9.97 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $8.74, XERS trades 14.1% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting XERS's risk profile.
RELATIVE · 30%
Comparing XERS's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for XERS, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate XERS's fair value with your own inputs.
XERS DCF Calculator
Pre-filled with XERS's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter XERS's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of XERS's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare XERS against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for XERS.
Explore on BuliosFAQ
What is the fair price of XERS?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Xeris Biopharma Holdings, Inc. is $9.97. At the current market price of $8.74, XERS trades 14.1% below its calculated fair value.
Is XERS overvalued or undervalued?+
Xeris Biopharma Holdings, Inc. is currently undervalued based on our valuation model. The stock trades at $8.74, which is 14.1% below the fair price of $9.97.
What is the margin of safety for XERS?+
With a 20% margin of safety applied to the fair price of $9.97, the conservative entry level for XERS is $7.98. At the current market price of $8.74, the stock trades 8.7% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is XERS's fair price updated?+
We update fair price calculations for XERS daily after market close. The current fair price of $9.97 incorporates the latest market data and sector multiples.
What factors affect XERS's fair price calculation?+
XERS's fair price of $9.97 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)..
Is XERS a good buy right now?+
At $8.74, XERS trades 14.1% below our fair value estimate of $9.97. The stock is currently undervalued. Fair Price Index provides valuation data — always do your own research before investing.
Does XERS pay dividends?+
XERS does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.